Stock ATT ATTENDO AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Attendo AB

Equities

ATT

SE0007666110

Healthcare Facilities & Services

Market Closed - Nasdaq Stockholm
Other stock markets
 08:59:54 03/05/2024 pm IST 		5-day change 1st Jan Change
43.45 SEK -0.46% Intraday chart for Attendo AB +2.72% +20.36%
26/04 Tranche Update on Attendo AB (OM:ATT)'s Equity Buyback Plan announced on February 13, 2024. CI
24/04 Attendo AB Approves Dividend, Payable on 2 May, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 8,679 7,141 6,195 3,898 5,810 6,902 - -
Enterprise Value (EV) 1 20,510 19,401 19,559 18,196 19,636 22,261 22,020 20,759
P/E ratio 106 x -7.88 x 110 x -86.5 x 15.5 x 15.2 x 11.1 x 9.55 x
Yield - - - - 2.77% 2.75% 3.37% 3.57%
Capitalization / Revenue 0.73 x 0.58 x 0.48 x 0.27 x 0.34 x 0.36 x 0.34 x 0.33 x
EV / Revenue 1.72 x 1.58 x 1.52 x 1.26 x 1.14 x 1.17 x 1.08 x 0.99 x
EV / EBITDA 10.6 x 9.45 x 9.03 x 8.37 x 6.45 x 6.6 x 6.04 x 5.55 x
EV / FCF 23.3 x 10 x 16.2 x 10.1 x - 16.5 x 9.21 x 8.21 x
FCF Yield 4.3% 9.96% 6.18% 9.93% - 6.06% 10.9% 12.2%
Price to Book 1.49 x 1.47 x 1.26 x 0.78 x 1.08 x 1.12 x 1 x 0.77 x
Nbr of stocks (in thousands) 1,60,879 1,60,913 1,60,913 1,60,933 1,60,933 1,58,842 - -
Reference price 2 53.95 44.38 38.50 24.22 36.10 43.45 43.45 43.45
Announcement Date 13/02/20 10/02/21 10/02/22 10/02/23 08/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,935 12,288 12,867 14,496 17,287 19,013 20,393 21,021
EBITDA 1 1,940 2,053 2,166 2,174 3,045 3,371 3,647 3,737
EBIT 1 672 673 755 616 1,274 1,430 1,631 1,748
Operating Margin 5.63% 5.48% 5.87% 4.25% 7.37% 7.52% 8% 8.31%
Earnings before Tax (EBT) 1 107 -926 103 -42 478 580.9 796 927.8
Net income 1 81 -904 56 -45 376 453.4 620.9 723.7
Net margin 0.68% -7.36% 0.44% -0.31% 2.18% 2.38% 3.04% 3.44%
EPS 2 0.5100 -5.630 0.3500 -0.2800 2.330 2.859 3.923 4.551
Free Cash Flow 1 882 1,932 1,208 1,806 - 1,348 2,390 2,530
FCF margin 7.39% 15.72% 9.39% 12.46% - 7.09% 11.72% 12.04%
FCF Conversion (EBITDA) 45.46% 94.11% 55.77% 83.07% - 39.99% 65.53% 67.7%
FCF Conversion (Net income) 1,088.89% - 2,157.14% - - 297.33% 384.92% 349.61%
Dividend per Share 2 - - - - 1.000 1.195 1.465 1.550
Announcement Date 13/02/20 10/02/21 10/02/22 10/02/23 08/02/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 3,338 3,482 3,546 3,679 3,789 4,044 4,801 4,810 4,881
EBITDA 1 511 507 481 673 513 - 773 1,015 810
EBIT 1 159 127 91 281 117 226 277 522 327
Operating Margin 4.76% 3.65% 2.57% 7.64% 3.09% 5.59% 5.77% 10.85% 6.7%
Earnings before Tax (EBT) 1 - -42 -68 121 -53 36 67 308 110
Net income 1 -9 -33 -63 95 -44 28 52 241 86
Net margin -0.27% -0.95% -1.78% 2.58% -1.16% 0.69% 1.08% 5.01% 1.76%
EPS 2 - - - - - - 0.3300 1.510 0.5400
Dividend per Share - - - - - - - - -
Announcement Date 10/02/22 06/05/22 21/07/22 26/10/22 10/02/23 26/04/23 - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 11,831 12,260 13,364 14,298 13,826 15,359 15,118 13,857
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 6.098 x 5.972 x 6.17 x 6.577 x 4.541 x 4.557 x 4.145 x 3.708 x
Free Cash Flow 1 882 1,932 1,208 1,806 - 1,348 2,390 2,530
ROE (net income / shareholders' equity) 1.39% -17% 4.87% -0.91% 7.26% 7.93% 9.68% 8.66%
ROA (Net income/ Total Assets) 0.39% -4.49% - -0.21% 1.66% 1.84% 2.42% 2.67%
Assets 1 20,748 20,126 - 21,700 22,608 24,693 25,636 27,134
Book Value Per Share 2 36.20 30.10 30.70 31.10 33.30 38.70 43.30 56.40
Cash Flow per Share 7.630 14.10 8.560 - - - - -
Capex 1 345 345 142 187 133 189 200 209
Capex / Sales 2.89% 2.81% 1.1% 1.29% 0.77% 0.99% 0.98% 0.99%
Announcement Date 13/02/20 10/02/21 10/02/22 10/02/23 08/02/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Attendo AB

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
43.45 SEK
Average target price
52.5 SEK
Spread / Average Target
+20.83%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
ATTENDO AB Stock Attendo AB
+20.36% 639M
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.70% 80.61B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-29.20% 70.18B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+9.86% 29.08B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-11.43% 16.97B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-0.43% 16.96B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-0.31% 15.26B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
+3.42% 12.41B
PURE HEALTH HOLDING Stock Pure Health Holding
-30.70% 11.95B
REDE D'OR SÃO LUIZ S.A. Stock Rede D'Or São Luiz S.A.
-6.75% 11.93B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. ATT Stock
  4. Financials Attendo AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW